Shubhanchi Nigam

Shubhanchi Nigam's work experience includes:

- Principal Scientist position at GSK starting in April 2023.

- Scientist role at Spark Therapeutics, Inc. from February 2022 to April 2023.

- Scientist role at Eurofins Lancaster Laboratories (Onsite - Janssen pharmaceuticals) from June 2020 to February 2022, responsible for data review, troubleshooting, and method development for antibody testing.

- Postdoctoral Research Associate at the University of Pittsburgh (Radiology department) from March 2017 to June 2020, where they developed and optimized PET tracers for melanoma and glioblastoma imaging.

Shubhanchi Nigam completed their education at various institutions. In 2007, they pursued a Master of Science (MSc) degree in Biochemistry from Chatrapati Sahuji Maharaj Kanpur University, Kanpur. Shubhanchi then continued their studies and obtained a European Master's degree in Quality in Analytical Chemistry from Gdansk University of Technology, University of Algarve, and University of Barcelona, spanning from 2009 to 2011. Currently, Shubhanchi Nigam is enrolled in a PhD program in Molecular Imaging at the University of Hull.